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Background:
STAT3 signaling has been shown to play a role 
in almost all aspects of cancer biology 
including anti-apoptosis, cell transformation, 
growth and proliferation, angiogenesis, 
metastasis and cancer stem cell maintenance. A 
large amount of clinical and preclinical data in 
solid and hematological cancers supporting 
STAT3 as a therapeutic target. As a result, there 
are a number of STAT3 inhibitors in clinical 
trials and many more in active development. 
TTI-101 currently in phase 1 clinical trials is a 
STAT3 inhibitor that competitively inhibits 
STAT3 activation by directly targeting the pY-
peptide binding site within STAT3’s SH2 
domain, thus blocking key steps in its activation 
process, starting with the recruitment to 
activated cytokine and peptide hormone 
receptors and consequently; cytokine dependent 
homodimerization, nuclear translocation and 
DNA binding. In this work we generated and 
characterized breast cancer cell lines MDA-
MB-468 for validation of mechanism of STAT3 
inhibitor TTI-101 
Figure 2. tSTAT3 and pSTAT3 Levels in Breast Cancer 
Cell Lines. Various cell lines were previously analyzed 
for tSTAT3 and pSTAT3 activity. The cell line MDA MB 
468 shows high levels of both pSTAT3 and tSTAT3, 
making it a good candidate for further investigation.
Conclusions
Optimal experimental treatment conditions of 
IL6 exposure length and TTI-101 concentration 
were identified. These conditions will guide 
future experiments to further investigate the 
impact of TTI-101 on MDA MB 468 cells. The 
KO Clone identities were confirmed and can be 
used in larger experiments. Y705H mutants were 
found to behave similar to KO cells upon 
exposure. Although, future experiments are 
needed to determine the exact changes ongoing 
in the cells.
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Results:
CRISPR-Cas9 approach was used to assess 
the genetic effects of STAT3 blockade. 
Three different types of MDA MB 468 cell 
lines were generated; STAT3 knockout 
(KO), STAT3 Y705H mutants and STAT3 
WT controls. The cells were sequenced to 
confirm changes at the DNA level. Absence 
of STAT3 protein expression of knockout 
clones and response to IL6 was confirmed 
using western blot analysis.
Optimal conditions for IL6 stimulation and 
TTI-101 treatment were determined using 
western blot analysis, real time PCR and 
immunofluorescence. The results show that 
maximum STAT3 phosphorylation was 
achieved after 15min of 100ng/ml IL6 
treatment. TTI-101 at a concentration of 
33uM was shown reduce IL6 dependent 
phosphorylation by more than 90% after 
4Hrs of pretreated. Importantly, levels of 
tSTAT3 and beta actin remained unchanged 
at this concentration. Immunofluorescence 
data showed that Y705H mutated cells 
prevented STAT3 from translocating to the 
nucleus in response to IL6 stimulation, 
showing that nuclear translocation is 
dependent on phosphorylation at Y705. 
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Materials and Methods:
15 MDA MB breast cancer cells were 
cultured in DMEM, 10% FBS at 37°C with 
an atmosphere of 5% CO2. Protein 
expression was analyzed with western blots 
as well as Luminex Assay. STAT3 activation 
was also examined using by the TransAM® 
STAT3 Activation Assay. 
Immunofluorescence microscopy was used 
to visualize nuclear translocation. qPCR was 
utilized to measure the effect of TTI-101 
exposure on the expression of STAT3 
dependent genes: CCL2, IL8, MUC1, SOC3, 
and Cyclin D1.
Hypothesis:
Our primary hypothesis is that the genetic 
inactivation of STAT3 by mutating the key Y705 
residue to H705 will elicit changes in the 
transcriptome of breast cancer cell lines similar 
to those observed with STAT3 inhibitor TTI-101.
Figure 3. Confirmation of Presence of Y705H Mutation. 
Chromatogram showing pDNA sequencing results of WT 
and Y705H cell lines. The Y705H cell line shows a clear 










Figure 4. WB of wild type MDA MB 468 Cas9 Control 
Clone 8 Cells With IL6 Exposure. WT MDA-MB-468 
Cells were stimulated with or without IL6 and IL6SR 
(100ng/ml) at the time points listed above. Protein lysates 
were analyzed by western blot using antibodies to pSTAT3 
and tSTAT3. Cells stimulated with IL6 show an increase in 
pSTAT3 up until 30 minutes after exposure, where at that 
point, pSTAT3 decrease. Cells with no IL6 exposure 
exhibit low, baseline pSTAT3 activity. tSTAT3 stays 
























































































































Figure 1. STAT3 Signaling Cascade. The STAT3
signaling pathway is initiated by cytokine binding.
Leading to receptor activation, STAT3 recruitment,
phosphorylation, dimerization, nuclear localization , DNA
binding and ultimately transcriptional activation of
specific genes.
Figure 5. WB of wild type MDA MB 468 Cas9 
Control Clone 8 Cells With TTI-101 Treatment. 
Cells were subject to varying TTI-101 concentrations 
for 4 hours. They were then stimulated with IL6 for 15 
minutes. pSTAT3 expression decreases as the 
concentration of TTI-101 increases. tSTAT3 expression 
stays consistent up until 100 µM where there is a sharp 
decrease in expression.
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Figure 6. Confirmation of KO Clones. Cells were 
exposed to IL6 for 15 minutes. STAT3 KO clones, as 
shown in bolded brackets, show no pSTAT3 or tSTAT3 
expression. The Y705H clones show no pSTAT3 activity, 
while maintaining their tSTAT3 activity.
Figure 7. STAT3 Activation Assay. Cells were exposed to 
IL6 and measured for their STAT3 activation (DNA binding 
activity). KO and Y705H clones show significantly less 
STAT3 activation than the controls when exposed to IL6.
(Red vs corresponding black bars)
Figure 8. Immunofluorescence Microscopy of Y705H 
Mutants. All cell lines were exposed to IL6 for 15 minutes 
and fixed with 4% paraformaldehyde. In all of the Y705H 
mutants, STAT3 does not translocate to the nucleus, as 
depicted in green, when exposed to IL6. The control clone 
shows STAT3 once translocated to the nucleus.
